Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis.

EBioMedicine - 1 Sept 2022

Chaytow Helena, Carroll Emily, Gordon David, Huang Yu-Ting, van der Hoorn Dinja, Smith Hannah Louise, Becker Thomas, Becker Catherina Gwynne, Faller Kiterie Maud Edwige, Talbot Kevin, Gillingwater Thomas Henry

Abstract excerpt

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with heterogeneous aetiology and a complex genetic background. Effective therapies are therefore likely to act on convergent pathways such as dysregulated energy metabolism, linked to multiple neurodegenerative diseases including ALS. METHODS: Activity of the glycolysis enzyme phosphoglycerate kinase 1 (PGK1) was increased...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Motor Neurons

Share to Phenotype

Share to Phosphoglycerate Kinase

Share to Zebrafish

Source

Open in PubMed Open full text

Identifiers

PMID: 35963713
DOI: 10.1016/j.ebiom.2022.104202
PMCID: PMC9482929

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis.PMID 35963713Read ↗

Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophySemantic proximity Read ↗

Phosphoglycerate kinase 1 as a therapeutic target in neurological diseaseSemantic proximity Read ↗

Mutant TDP-43 drives impairments in axonal transport and glycolysis in a mouse stem-cell-derived motor neuron model of amyotrophic lateral sclerosis (ALS).Semantic proximity Read ↗

Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALSSemantic proximity Read ↗

Abnormal energy metabolism in ALS: a key player?Semantic proximity Read ↗

Targeting energy metabolism in Huntington's disease.Semantic proximity Read ↗

Why TDP-43? Why Not? Mechanisms of Metabolic Dysfunction in Amyotrophic Lateral SclerosisSemantic proximity Read ↗

Analyzing ER stress response in ALS patient derived motor neurons identifies druggable neuroprotective targetsSemantic proximity Read ↗

Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice.Semantic proximity Read ↗

Intrinsic and extrinsic regulation of rhabdomyolysis susceptibility by Tango2.Semantic proximity Read ↗

Meclizine is neuroprotective in models of Huntington's diseaseSemantic proximity Read ↗

Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.